Published • loading... • Updated
AbbVie to Acquire Apogee, Staking Nearly $11B on Long-Acting Autoimmune Drugs
The deal gives AbbVie access to zumilokibart, an experimental treatment tested for atopic dermatitis and asthma, as pharmaceutical companies race to replace blockbuster revenue.
- On Monday, AbbVie announced plans to acquire Apogee Therapeutics for $10.9 billion, marking its largest buyout in more than five years as it strengthens its immunology pipeline.
- Aiming to bolster its inflammatory disease portfolio, AbbVie seeks to maintain market dominance as Humira goes off-patent, building on its $63 billion 2019 Allergan acquisition.
- Apogee's lead candidate, zumilokibart, offers two to four injections annually for atopic dermatitis and asthma, providing a more convenient dosing schedule than Sanofi and Regeneron Pharmaceuticals' Dupixent.
- RBC Capital Markets analyst Brian Abrahams called the buyout an "ideal and sensible outcome," though he noted it occurred "earlier than we would have expected."
- Pharmaceutical dealmaking has surged as companies build portfolios ahead of looming patent expirations, with BioPharma Dive data indicating 2026 totals are on pace to surpass every year since at least 2020.
Insights by Ground AI
14 Articles
14 Articles
With its largest acquisition in more than five years, Abbvie strengthens its own pharmaceutical pipeline. The company's acquisition secures access to several active ingredients.
·Düsseldorf, Germany
Read Full Article
AbbVie agreed to acquire Apogee Therapeutics for about US$10.9 billion in cash, in an agreement that reinforces the portfolio of immunology and inflammation of pharmaceuticals. Exclusive material for subscribers. To have full access, access the link of the material and register.
·Brazil
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left1Leaning Right2Center8Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
C 73%
R 18%
Factuality
To view factuality data please Upgrade to Premium
